5 results about "Pleuropneumonia" patented technology

The invention belongs to the technical field of biology, and particularly relates to a nasal spray sheep contagious pleuropneumonia subunit vaccine and a preparation method thereof. Comprising a first antigen protein and a second antigen protein, the amino acid sequence of the first antigen protein is shown as SEQ NO: 1, and the amino acid sequence of the second antigen protein is shown as SEQ NO: 2. The mass ratio of the first antigen protein to the second antigen protein is 1: (1-1.5). Ca < + > can stabilize an antigen protein structure through an ionic bond and reduce degradation of the antigen protein in nasal mucosa secretions, when tannic acid is combined with a Ca < + >-antigen compound, a more ordered immunogenic compound can be formed through the synergistic effect of polyphenol-metal ion-protein, so that part of antigen is changed into particles, and the stability of the antigen is improved. PDA can wrap a compound, firm attachment is formed in a nasal mucosa moist environment by means of the bionic adhesion characteristic of PDA, the antigen exposure time is prolonged, and continuous generation of antibodies is promoted.

This invention relates to the field of molecular biology, specifically to a nested PCR primer set, kit, and application for detecting porcine infectious pleuropneumonia. The kit, developed by establishing a nested PCR amplification primer set, can be used for the in vitro diagnosis of porcine infectious pleuropneumonia. It exhibits high sensitivity, detecting up to 0.355 pg / µL, which is nearly 100 times higher than that of conventional PCR (35.5 pg / µL). It also demonstrates strong specificity, overcoming the problems of low sensitivity and poor specificity associated with conventional PCR. Compared to existing indirect immunofluorescence and serological detection methods, it offers lower cost and a shorter detection cycle.

This invention discloses a Mycoplasma caprineis subspecies Mccp NM strain and its applications. Whole-genome alignment of this strain revealed 422 missense mutations, 132 frameshift mutations, and several key insertion / deletion variations compared to the existing vaccine strain C87001. In virulence studies, at a concentration of 1×10⁻⁶... 9 In healthy, susceptible goats, intratracheal injection at a CCU / mL dose resulted in all experimental goats exhibiting typical symptoms of caprine contagious pleuropneumonia. Autopsy revealed pleural effusion and liver-like lesions in the lungs. The inactivated vaccine prepared using this strain demonstrated good safety in goats. Challenge protection tests showed that the vaccine of this invention provided 100% protection against homologous challenge with the NM strain and 80% protection against the heterologous C87002 strain, while commercially available vaccines offered only 40% protection against the NM strain. This invention overcomes the deficiency of existing vaccines in providing insufficient protection against clinical variants, offering an effective technical reserve and candidate vaccine for addressing immunization failure caused by Mccp antigen mutations.

This invention relates to the fields of veterinary immunology and molecular biology, and discloses a goat cytokine composition with immune-enhancing effects and its applications. The composition comprises recombinant goat cytokines IL-9 and IL-21, whose amino acid sequences are shown in SEQ ID NO. 8 and SEQ ID NO. 12, respectively. These two cytokines upregulate the expression of IL-2, IL-4, IFN-γ, IL-17, and TNF-α in goat PBMCs, stimulating Th1, Th2, and Th17 immune responses in goats. When used in combination with an inactivated goat infectious pleuropneumonia vaccine, this goat cytokine composition exhibits good immune-enhancing effects and shows potential application prospects. This goat cytokine composition has advantages such as ease of preparation, high yield, good stability, and low production cost.

This invention belongs to the field of biotechnology, specifically relating to a nasal spray subunit vaccine for ovine infectious pleuropneumonia and its preparation method. It includes a first antigen protein and a second antigen protein, the amino acid sequence of which is shown in SEQ NO:1, and the amino acid sequence of which is shown in SEQ NO:2. The mass ratio of the first antigen protein to the second antigen protein is 1:(1-1.5). This invention [Ca²] + It can stabilize the structure of antigen proteins through ionic bonds, reducing their degradation in nasal mucosal secretions. Tannic acid and Ca²⁺ + When antigen complexes bind, they can form more ordered immunogenic complexes through the synergistic effect of polyphenols, metal ions, and proteins, making some antigens particulate and enhancing the uptake and processing efficiency of antigen-presenting cells. PDA can encapsulate the complex and use its biomimetic adhesion properties to form a firm attachment in the moist environment of the nasal mucosa, prolonging the antigen exposure time and promoting the continuous production of antibodies.